Business

Summit Therapeutics to raise USD 500m via public offering as ivonescimab trials progress

Edited by Robert McTiernan··3 min read
Summit Therapeutics to raise USD 500m via public offering as ivonescimab trials progress

Miami-based Summit Therapeutics Inc. (Nasdaq: SMMT) announced a proposed underwritten public offering of common stock targeting USD 500 million in gross proceeds, with the capital earmarked to fund continued clinical development of ivonescimab, its sole pipeline asset, across licensed territories including the US, Canada, Europe, Japan, and more recently Latin America, the Middle East, and Africa. The offering reflects the capital intensity of running multiple global Phase III oncology trials on a single-asset platform, and follows two private placements in 2024 that collectively raised USD 435 million.

The offering is structured as a primary issuance, with all shares sold by Summit and no selling shareholders. Underwriters have been granted a 30-day overallotment option to purchase up to an additional USD 75 million in shares at the public offering price, bringing the potential total to USD 575 million. Specific share count and pricing had not been disclosed at the time of announcement.

Company overview and pipeline

Summit is a single-asset oncology company whose entire clinical and commercial strategy is built around ivonescimab (SMT112), a bispecific antibody that simultaneously targets PD-1 and VEGF. The molecule was in-licensed exclusively from China-based Akeso Inc. (HKEX: 9926) in a deal announced in December 2022 and closed in January 2023, with an upfront payment of USD 500 million and potential milestones of up to USD 4.5 billion, plus low double-digit royalties on net sales. Summit holds rights in the US, Canada, Europe, Japan, and — following a June 2024 territory expansion amendment — Latin America, the Middle East, and Africa.

Ivonescimab is being evaluated in a Phase III program for non-small cell lung cancer and other solid tumors within Summit's licensed territories. Investor interest in the asset has been sustained by clinical data from Akeso's own trials suggesting competitive differentiation versus pembrolizumab (Keytruda) in NSCLC, though Summit is running independent registrational studies to support regulatory filings in its own markets. The company has no other disclosed pipeline assets; its capital allocation is entirely concentrated on ivonescimab's development and eventual commercialization.

The AllSci BriefSystematic R&D and deal news. Daily.

Summit's recent financing cadence has been aggressive. A USD 200 million private placement in June 2024, described as unsolicited and priced at a premium to the prior closing price, was followed in September 2024 by a USD 235 million insider- and institution-led private placement priced at USD 22.70 per share. The current USD 500 million offering, if completed at full size including the overallotment, would represent the largest single capital raise in the company's history and would substantially extend its operational runway for late-stage development.

In the broader PD-1/VEGF bispecific space, ivonescimab competes conceptually with assets from larger platforms, though no directly comparable approved bispecific combining these two targets exists in Summit's licensed markets. The primary competitive benchmark remains pembrolizumab monotherapy and combination regimens in first-line NSCLC, making Summit's Phase III readouts the critical value inflection for the asset's commercial case.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article